| Biopharmaceutical challenges associated with drugs with low aqueous solubility—the potential impact of lipid-based formulations CM O'driscoll, BT Griffin Advanced drug delivery reviews 60 (6), 617-624, 2008 | 365 | 2008 |
| Gut reactions: breaking down xenobiotic–microbiome interactions G Clarke, KV Sandhu, BT Griffin, TG Dinan, JF Cryan, NP Hyland Pharmacological reviews 71 (2), 198-224, 2019 | 292 | 2019 |
| Lipid-based nanocarriers for oral peptide delivery Z Niu, I Conejos-Sánchez, BT Griffin, CM O’Driscoll, MJ Alonso Advanced drug delivery reviews 106, 337-354, 2016 | 251 | 2016 |
| Interactions between antidepressants and P‐glycoprotein at the blood–brain barrier: clinical significance of in vitro and in vivo findings FE O'Brien, TG Dinan, BT Griffin, JF Cryan British journal of pharmacology 165 (2), 289-312, 2012 | 234 | 2012 |
| Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: An UNGAP review Z Vinarov, M Abdallah, JAG Agundez, K Allegaert, AW Basit, ... European Journal of Pharmaceutical Sciences 162, 105812, 2021 | 203 | 2021 |
| From belly to brain: targeting the ghrelin receptor in appetite and food intake regulation K Howick, BT Griffin, JF Cryan, H Schellekens International journal of molecular sciences 18 (2), 273, 2017 | 170 | 2017 |
| Focus: microbiome: the impact of the gut microbiota on drug metabolism and clinical outcome EF Enright, CGM Gahan, SA Joyce, BT Griffin The Yale journal of biology and medicine 89 (3), 375, 2016 | 154 | 2016 |
| Comparison of in vitro tests at various levels of complexity for the prediction of in vivo performance of lipid-based formulations: case studies with fenofibrate BT Griffin, M Kuentz, M Vertzoni, ES Kostewicz, Y Fei, W Faisal, C Stillhart, ... European Journal of Pharmaceutics and Biopharmaceutics 86 (3), 427-437, 2014 | 134 | 2014 |
| Lipophilicity and hydrophobicity considerations in bio-enabling oral formulations approaches–a PEARRL review F Ditzinger, DJ Price, AR Ilie, NJ Köhl, S Jankovic, G Tsakiridou, ... Journal of Pharmacy and Pharmacology 71 (4), 464-482, 2019 | 113 | 2019 |
| Drug–gut microbiota interactions: implications for neuropharmacology J Walsh, BT Griffin, G Clarke, NP Hyland British journal of pharmacology 175 (24), 4415-4429, 2018 | 112 | 2018 |
| Food for thought: formulating away the food effect–a PEARRL review JP O'Shea, R Holm, CM O'Driscoll, BT Griffin Journal of Pharmacy and Pharmacology 71 (4), 510-535, 2019 | 106 | 2019 |
| Pharmacotherapy for neonatal seizures: current knowledge and future perspectives MD Donovan, BT Griffin, L Kharoshankaya, JF Cryan, GB Boylan Drugs 76 (6), 647-661, 2016 | 105 | 2016 |
| Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network Z Vinarov, B Abrahamsson, P Artursson, H Batchelor, P Berben, ... Advanced Drug Delivery Reviews 171, 289-331, 2021 | 102 | 2021 |
| Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel SJ Cushen, DG Power, KP Murphy, R McDermott, BT Griffin, M Lim, ... Clinical nutrition ESPEN 13, e39-e45, 2016 | 102 | 2016 |
| Regulation of biosimilar medicines and current perspectives on interchangeability and policy J O’Callaghan, SP Barry, M Bermingham, JM Morris, BT Griffin European journal of clinical pharmacology 75, 1-11, 2019 | 100 | 2019 |
| Pharmacokinetic, pharmacodynamic and biodistribution following oral administration of nanocarriers containing peptide and protein drugs BT Griffin, J Guo, E Presas, MD Donovan, MJ Alonso, CM O'Driscoll Advanced Drug Delivery Reviews 106, 367-380, 2016 | 97 | 2016 |
| Lactococcus lactis as a cell factory for delivery of therapeutic proteins M Bahey-El-Din, CGM Gahan, BT Griffin Current gene therapy 10 (1), 34-45, 2010 | 97 | 2010 |
| A comparison of intestinal lymphatic transport and systemic bioavailability of saquinavir from three lipid‐based formulations in the anaesthetised rat model BT Griffin, CM O'driscoll Journal of pharmacy and pharmacology 58 (7), 917-925, 2006 | 96 | 2006 |
| Microbiome-mediated bile acid modification: role in intestinal drug absorption and metabolism EF Enright, BT Griffin, CGM Gahan, SA Joyce Pharmacological Research 133, 170-186, 2018 | 82 | 2018 |
| The pig as a preclinical model for predicting oral bioavailability and in vivo performance of pharmaceutical oral dosage forms: a PEARRL review LJ Henze, NJ Koehl, JP O'Shea, ES Kostewicz, R Holm, BT Griffin Journal of pharmacy and pharmacology 71 (4), 581-602, 2019 | 71 | 2019 |
